No fees unless we win.
Get a free consultation
According to the Charleston Gazette, drug manufacturer GlaxoSmithKline has agreed to pay the state of West Virginia $22 million to settle a lawsuit that alleged the company illegally promoted its diabetes medicine Avandia.
The news outlet reported that the drug maker announced the settlement originally with West Virginia and seven other states in a regulatory filing in July 2013. However, the settlement was just signed off on by West Virginia Attorney General Patrick Morrisey on May 30.
Morrisey reportedly told the news outlet that it is one of the largest drug lawsuit settlements in the state’s history.
“This settlement is a significant victory for the state, its agencies and the people,” Morrisey said in a statement. “We are pleased that we were able to recoup some of the money spent on these products.”
GSK denied any wrongdoing as part of the settlement. The lawsuit alleged that the company failed to disclose side effects of Avandia, which include heart problems and lowered blood sugar in users. The drug has also been linked to strokes.
“Our citizens have the right to know the risks and possible side effects of the medication they are taking,” Morrisey said, according to the Gazette.
The newspaper reported that in November 2012, GSK agreed to pay $90 million to settle Avandia-related lawsuits in 37 states. West Virginia was one of eight states that opted out of the agreement.
Have You Had a Family Member Killed or Injured By Avandia?
Although the US Food and Drug Administration (FDA) restricted Avandia use in 2010, many of the limitations were lifted in December 2013. The drug has been linked to thousands of heart attacks and strokes among users.
The drug belongs to a class of medication called thiazolidinediones, which also includes the drug Actos that has been linked to bladder cancer.
If you or someone you love has suffered an injury while taking Avandia or Actos, contact us today. We can investigate your case and seek compensation if the dangerous drugs harmed you.
Zoll, Kranz & Borgess, LLC – Defective Medical Drug and Device Lawyers
ZKB’s ‘Did You Know’? Avandia was once one of the U.S.’s most popular Type 2 diabetes medications.
Source: http://www.wvgazette.com/article/20140612/GZ01/140619704/1419
Michelle is a founding partner of Zoll & Kranz, located in Toledo, Ohio. Michelle has been a plaintiff’s lawyer for the entirety of her practice – over 32 years. She devotes the majority of her time to complex consolidated litigation and class action including advocating for people injured by medical devices, prescription medications, or corporate negligence.
This article has been written and reviewed for legal accuracy and clarity by the team of writers and attorneys at Zoll & Kranz, LLC and is as accurate as possible. This content should not be taken as legal advice from an attorney. If you would like to learn more about our owner and experienced Ohio injury lawyer, Michelle L. Kranz, you can do so here.
Zoll & Kranz, LLC does everything possible to make sure the information in this article is up to date and accurate. If you need specific legal advice about your case, contact us. This article should not be taken as advice from an attorney.
A serious injury can have life-altering results.
Don’t settle for less than you deserve, speak with an award-winning personal injury lawyer today.
FDA Warns Pfizer’s Drug Tygacil Raises Risk of Death
FDA Announces da Vinci Surgical System Robot Recall
FDA Issues Warning Over Phillips Heart Defibrillators
FDA Issues Warning About Medtronic Guidewire Recall
Unsterile Medical Device Recall: Zoll & Kranz, LLC is investigating the Seprafilm Class II Recall
For over 37 years, Zoll & Kranz has been fighting for clients who have been the victims of the wrongful death of a loved one.
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
A serious injury can have life-altering results.
Don’t settle for less than you deserve, speak with an award-winning personal injury lawyer today.
